A microplate-based electrophoretic assay has been developed for the serine/threonine kinase protein kinase A (PKA). The ElectroCapture™ PKA assay developed uses a positively charged, lissamine-rhodamine-labeled kemptide peptide substrate for the kinase reaction and Nanogen's ElectroCapture™ HTS Workstation and 384-well laminated membrane plates to electrophoretically separate the negatively charged phosphorylated peptide product from the kinase reaction mix. After the electrophoretic separation, the amount of rhodamine-labeled phosphopeptide product was quantified using a Tecan Ultra384 fluorescence reader. The ElectroCapture™ PKA assay was validated with both known PKA inhibitors and library compounds. The pK i app results obtained in the ElectroCapture™ PKA assay were comparable to those generated with current radioactive filter-binding assay and antibody-based competitive fluorescence polarization PKA assay formats. (Journal of Biomolecular Screening 2005:329-338) 
P ROTEIN KINASES ARE KEY MEDIATORS of signal transduction within eukaryotic cells. Aberrant protein phosphorylation and associated signal transduction have been implicated in a wide variety of human diseases including cancer, diabetes, and inflammation, making protein kinases attractive targets for drug discovery research. 1, 2 Protein kinases are enzymes that covalently modify proteins and peptides by the attachment of a phosphate group to 1 or more sites on the protein. Many of the known protein kinases use adenosine triphosphate (ATP) as the phosphate donor, placing the γ-phosphate onto a histidine, tyrosine, serine, or threonine residue in the protein.
Phosphorylation can alter certain structural, thermodynamic, and kinetic properties of the protein. Generally, each phosphate adds 2 negative charges to the protein. This modifies the electrostatic interactions between the protein's constituent amino acids, potentially altering the secondary and tertiary protein structure. The phosphate may also form up to 3 hydrogen bonds or salt bridges with other protein residues or may otherwise change the conformational equilibrium between different functional states of the protein. These structural changes provide the basis, in a biological system, for altering substrate binding and catalytic activity of the phosphorylated proteins.
Methods for assaying the activity of the protein kinases often use a synthetic peptide substrate that can be phosphorylated by the kinase protein under study. Historically, the most common mechanisms for detecting phosphorylation of the peptide substrates are 1) incorporation of 32 P (or 33 P) phosphate from [ 32 P]γ-ATP into the peptides, separation of the peptides from the ATP, and scintillation or Cerenkov counting of the incorporated radionucleotide; 2) detection of phospho-amino acids via the binding of phospho-specific antibodies; or 3) separation of phosphorylated and nonphosphorylated peptide substrates by chromatographic or electrophoretic methods, followed by quantification of the purified product.
Many high-throughput screening (HTS) kinase assays have been developed to use the above 3 methods, such as fluorescence polarization (FP), homogeneous time-resolved fluorescence, and radioactive assays such as filter-binding assays, Flashplate, and scintillation proximity assays. These assays require either antibod-ies for the detection or use of radioactivity. Currently, very few specific, high-affinity phospho-antibodies are available commercially. In most cases, the phospho-Ser/Thr antibodies will have to be developed on a substrate-by-substrate basis, which can add significant time to the assay development process. Use of radioactivity poses other significant disadvantages such as cost, waste disposal, and exposure hazard posed to the personnel working with the isotope. 3, 4 In the past 2 to 3 years, a variety of new fluorescence-based homogenous assay formats have been developed and are being marketed as "plug-and-play" kinase assay kits by a number of vendors. [5] [6] [7] Even if the ease of use and ability to minimize cost through miniaturization are achievable, the potential for compound fluorescence interference (especially for homogenous assay formats using low concentrations of fluorescently labeled substrate or tracer) will still need to be assessed to determine the potential limitations of each kit. 8 To address many of the aforementioned issues, a nonhomogenous electrophoretic, fluorescent microplate-based ElectroCapture™ assay was developed for protein kinase A (PKA), which does not use radioactivity or antibodies.
PKA, also known as cyclic AMP-dependent protein kinase is one of the first and best characterized of the serine/threonine protein kinases. As such, there are many well-characterized pharmacological inhibitors, and much is known regarding the in vitro kinetics of PKA. 9 Kemp and coworkers described the development of an in vitro PKA assay using the peptide sequence LRRASLG (kemptide). 10 Herein, we describe the principles of the electrophoretic, fluorescent PKA assay that uses lissamine-kemptide as a substrate and the fundamentals of the ElectroCapture™ technology and ElectroCapture™ HTS Workstation that we have developed. We also present results for a PKA ElectroCapture™ assay developed using this technology for determining kinase enzymatic reaction time courses, enzyme kinetics, and dose-response curves for known inhibitors. Finally, we compare the compound inhibitor screening results obtained with the ElectroCapture™ assay to those obtained using filter-binding and FP technologies at Eli Lilly, a beta-test site for the ElectroCapture™ technology.
MATERIALS AND METHODS

ElectroCapture™ technology
The ElectroCapture™ technology combines electric field separation of a substrate and a reaction product of different net charge and subsequent capture of the reaction product on a capture matrix (see Fig. 1 ). The electrophoretic separation occurs in a vertical direction within each well of the 384-well ElectroCapture™ plate. When voltage is applied across each well, the negatively charged phosphorylated peptides migrate (electrophorese) through a diffusion barrier and then bind to a membrane at the bottom of the well. In general, a net charge inversion must occur on the fluorescently tagged substrate for detection by ElectroCapture™. For kinase assays, the substrates must have a net positive (+1) charge. Several The ElectroCapture™ assay. The fluorescently labeled substrate contains a +1 charge. Upon phosphorylation, the peptide substrate undergoes a charge inversion from a +1 charge to a -1 charge on the product of the reaction. When an electric field is applied, the unphosphorylated peptide substrate +1 migrates toward the negative electrode, and the product -1 migrates toward the positive electrode. The -1 charged phosphorylated peptides migrate toward the positive electrode from the solution, through the diffusion barrier, and bind to the membrane. ATP = adenosine triphosphate.
ElectroCapture™ assays have been developed in which although the known peptide substrate did not contain a net positive (+1) charge, charged residues (e.g., lysine and glutamic acid residues) were added to the peptide sequence to engineer a peptide with an appropriate net positive (+1) charge (data not shown). Then, after the kinase reaction is complete, the quenched enzymatic reaction mixture is placed into an ElectroCapture™ plate: a 384-well laminated membrane plate containing an electrophoresis buffer and a diffusion barrier deposited on the membrane of each well. The ElectroCapture™ plate is placed in a lower electrode bath that contains an electrophoresis buffer and forms the electro-fluidic connection to the reaction mixture through the membrane and the diffusion barrier. An electrode upper bath with an array of 384 rods is lowered into the ElectroCapture™ plate that forms the electrofluidic connection with the negative electrode. The upper and lower electrode baths are integrated into an automated workstation, the ElectroCapture™ HTS Workstation (see Fig. 2 ), described below. Across each well of the ElectroCapture™ plate, a voltage is applied, and electronic separation begins. The positively charged species migrate toward the negative electrode (upper electrode), and the negatively charged species migrate toward the positive electrode (lower electrode). For kinase reactions, the negatively charged species are fluorescently labeled phosphorylated peptides with a -1 net charge that migrate downward through the diffusion barrier and bind to the membrane that forms the bottom of each well. The positively charged fluorescently labeled unphosphorylated peptide migrates upward toward the negatively charged electrode in the upper electrode bath. Upon completion of the electrophoretic separation, the ElectroCapture™ plate is removed from the lower electrode bath, and the reaction mixture is removed from the wells by aspiration or washing with water. The fluorescence is read in a plate reader from the top of the plate, and the fluorescence intensity is directly proportional to the amount of phosphorylated peptide captured on the membrane in the bottom of the well.
ElectroCapture™ plates
The ElectroCapture™ plates are standard 384-well bottomless plates that have a membrane laminated to the polystyrene forming the bottoms of the wells. This membrane serves to bind the phosphorylated peptide during the electrophoretic separation of the unphosphorylated peptide and the phosphorylated peptide of the kinase reaction. To prevent immediate binding of all peptides to the membrane, a diffusion barrier has been applied to the top of the membrane. The diffusion barrier is a proprietary matrix applied to the membrane at the bottom of the ElectroCapture™ plate and is cured in place. (Note that without the diffusion barrier, all peptides would immediately bind to the surface of the membrane via random diffusion and adsorption. The diffusion barrier effectively slows the diffusion of the peptides, and when a voltage is applied, only the negatively phosphorylated peptides move through the diffusion barrier and bind to the membrane.) The standard 384-well format of the ElectroCapture™ plates enables liquid handling with 96-well and 384-well manual and robotic pipettors. In addition, the ElectroCapture™ plates can be read by standard 384-well fluorescence plate readers such as the Tecan™ SpectraFluor Plus, the Tecan™ Ultra, and the Tecan™ Safire.
ElectroCapture™ HTS Workstation
The ElectroCapture™ HTS Workstation was developed at Nanogen, Inc. to automate the electrophoretic separation of the phosphorylated and unphosphorylated peptides in the kinase reaction mixtures in the wells of the ElectroCapture™ plates (see Fig. 2). The system is controlled via Nanogen's custom software that runs macros to control the power supply for the electrophoresis, fluidics, and y-z motion. The ElectroCapture™ HTS Workstation contains a lower electrode reservoir to hold the ElectroCapture™ plate. This lower electrode reservoir has fluidics and sensors for filling and emptying the electrophoresis buffer as well as a platinum electrode to apply the voltage. An upper electrode reservoir also contains similar fluidics and buffer sensors and the upper electrode above the ElectroCapture™ plate. The electronic connection between the upper electrode and the lower electrode is facilitated through the reaction mixture in the wells by an array of 384 rods on the bottom surface of the upper electrode reservoir. These rods conduct electrical current but do not leak buffer. When not in use, the upper electrode head is stored in the park bath. In the beta version of the instrument, the park bath is merely a large reservoir of electrophoresis buffer that serves to both soak the rods to keep them hydrated and to rinse the rods between runs. A washing step (in which the park bath can be emptied and filled) for the upper electrodes is part of the ElectroCapture™ protocol for the automated production version of the instrument. The ElectroCapture™ plate containing the diluted reaction mixture is manually placed in the ElectroCapture™ HTS Workstation into the lower electrode reservoir, and the workstation runs the fluidics and electronics as set in the macros. During the electrophoresis, the applied voltage and real-time current can be monitored on the touch screen. At the completion of the electrophoresis, the ElectroCapture™ plate is removed by the user and placed in a 384-well plate washer to remove the unphosphorylated substrate from the well. Next, the fluorescence is read in a 384-well fluorescence plate reader. The fluorescence that is read is directly proportional to the amount of phosphorylated peptide captured on the bottom of the plate.
ElectroCapture™ K M determination protocol
The kinetics protocol for the ElectroCapture™ K M determination was composed of 3 transfers to the kinase reaction: substrate, enzyme, and ATP. The fluorophore-labeled substrate was prepared in the reaction wells with 2-fold serial dilutions into reaction buffer. The substrate concentrations were in the range of 200 µM to 0.4 µM, which corresponds to 10*K M > K M > 0.2*K M for the expected K M . Enzyme was added at a concentration previously determined to provide initial velocity kinetics. Quench wells were prepared with EDTA at 4× concentration of the MgCl 2 final concentration. ATP at a concentration of 100 to 200 µM was added to the wells to initiate the reaction. Aliquots were transferred from the reaction wells to the quench wells at timed intervals for 6 to 10 time points. At the completion of the time course, an ElectroCapture™ plate was prepared with 35 µL/well 100 mM Tris-Borate pH 8 buffer, and 5 µL of the quenched reaction mixture was added to the ElectroCapture™. plate. The ElectroCapture™ plate was then placed into the ElectroCapture™ HTS Workstation lower electrode reservoir, and the computer macro was started. The ElectroCapture™ Workstation then directed the lowering of the 384-well upper electrode reservoir into the ElectroCapture™ plate, the buffer reservoirs were filled with buffer, and a voltage of 160 V was applied across the plate to commence the electrophoresis. After the 7-min electrophoresis was completed, the upper electrode reservoir was returned to the holding bath, and the lower electrode reservoir was emptied. The ElectroCapture™ plate was then manually removed from the ElectroCapture™ HTS Workstation, and the remaining reaction mixture was then removed from the wells of the ElectroCapture™ plate, followed by a water wash/ aspiration via a 384-well plate washer. The fluorescence was read in a Tecan™ Ultra plate reader (λ ex = 535 nm, λ ex = 612 nm). From the initial rates of the reaction of PKA and lissamine-kemptide and ATP, an enzyme kinetics analysis was done to fit the data to a Michaelis-Menten kinetics model using a SigmaPlot™ Enzyme Kinetics module.
ElectroCapture™ IC 50 protocol
The kinase reaction mixture for the ElectroCapture™ IC 50 determinations consisted of 23 mM HEPES pH 7.4, 0.034% Triton X-100, 2 mM MgCl 2 , 0.113 mM DTT, 4% DMSO, 8 µM (0.5*K M ) lissamine kemptide peptide (Nanogen), 45 µM (4.5*K M ) ATP, and 0.26 mU/µL human PKA catalytic subunit type α enzyme (Upstate Biotechnologies, Inc.). Compound inhibitors were solu-bilized at 10 mM in 100% DMSO and then were diluted to 100 µM with 20% DMSO. Compound inhibitor serial dilutions (1:3) were prepared on a Tecan™ Genesis over a 100 µM to 0.005 µM range. Kinase reactions were performed in 96-well v-bottom polypropylene plates (Nunc). Eight 10-point IC 50 determinations and 16 controls (8 uninhibited "MAX" and 8 no-enzyme "MIN" control wells) were run per 96-well plate. The protocol for the ElectroCapture™ IC 50 determinations was composed of 3 transfers to the kinase reaction: 5 µL serially diluted compounds in 20% DMSO, 10 µL substrate/ATP, and 10 µL enzyme (or 10 µL enzyme dilution buffer for the 8 no-enzyme control wells). Kinase reactions were incubated at room temperature for 30 min (this reaction time had been determined experimentally to be within initial velocity kinetics for the assay), and then the reactions were quenched by the addition of 5 µL 130 mM EDTA pH 8.0. This produced a postquench reaction volume of 30 µL, which was enough to run 2 ElectroCapture™ separations per reaction well. At the completion of the reaction, an ElectroCapture™ plate was prepared by adding 35 µL/well of 10 mM Tris-Borate pH 8 buffer. Then, 5 µL of quenched reaction mixture was added to the ElectroCapture™ plate. The plate was placed on the ElectroCapture™ HTS Workstation, and the electrophoretic separations were conducted in the manner described above for 7 min at 160 V. Following the electrophoresis, the remaining reaction mixture was aspirated/washed from the wells, and the fluorescence was read using a Tecan™ Ultra 384 plate reader (λ ex = 535 nm, λ ex = 612 nm). Relative (vs. absolute) compound IC 50 values were determined by first converting the relative fluorescence units data to percentage inhibition with respect to onplate MIN and MAX controls and then fitting the percentage inhibition values and 10-point dose-response data to a 4-parameter logistic equation (Hill slope = 1) using ActivityBase (version 2.0, IDBS).
FP K M determination protocol
The RFARKGSLRQKNV peptide was the phosphate acceptor for hPKA FP assays (as there was a phospho-specific antibody available for this peptide). For the FP K M determinations, the reaction mixtures contained 23 mM HEPES (BRL-Gibco) pH 7.4, 0.034% Triton X-100 (Pierce), 2 mM MgCl 2 , 0.113 mM DTT, 4% DMSO, 3.4 nM 5-carboxyfluorescein-RFARKGSLRQKNV tracer (SynPep), and 0.003 mU/µL human PKA catalytic subunit type α enzyme (Upstate Biotechnologies, Inc.). To determine K M for ATP, the peptide concentration was held constant at 25 µM, and the ATP concentration was varied from 0 to 100 µM. To determine the K M for peptide, the ATP concentration was held constant at 100 µM, and the peptide concentration was varied from 0 to 20 µM. The time course reactions were initiated with the addition of enzyme and incubated at room temperature in a final reaction volume of 25 µL. Reactions were terminated with 25 µL of quench/ detection reagent containing 7.5 nM Anti-Phosphoserine RFARKGS(PO 4 )LRQKNV Antibody (MBL International) 11 and 130 mM EDTA pH 8.0. After the reactions were quenched, the plates were incubated in darkness at room temperature for 3 to 16 h, and then FP was measured at λ ex = 485 nm, λ ex = 530 nm, on an LJL Analyst™ (Molecular Devices) plate reader. The concentration of phosphorylated product per well was calculated from millipolarization (mP) using a prepared RFARKG(pS)LRQKNV competitor (SynPep) dilution series as a standard curve. For all reactions, product formation was linear with respect to time with less than 10% of the limiting substrate consumed during the reaction. Kinase reactions were incubated at room temperature for 60 min (this reaction time had been determined experimentally to be within initial velocity kinetics for the assay), and then the reactions were quenched by the addition of 25 µL of quench/ detection reagent containing 7.5 nM Anti-Phosphoserine RFARKGS(PO 4 )LRQKNV Antibody (MBL International) and 130 mM EDTA pH 8.0. After the reactions were quenched, the plates were incubated in darkness at room temperature for 3 to 16 h, and then FP was measured at λ ex = 485 nm, λ ex = 530 nm, on an LJL Analyst™ (Molecular Devices) plate reader. The concentration of phosphorylated product per well was calculated from millipolarization (mP) using a prepared RFARKG(pS)LRQKNV competitor (SynPep) dilution series as a standard curve. Relative (vs. absolute) compound IC 50 values were determined by first converting the calculated micromolar of phosphorylated product per well to percentage inhibition with respect to on-plate MIN and MAX controls and then fitting the percentage inhibition values and 10-point dose-response data to a 4-parameter logistic equation (Hill slope = 1) using ActivityBase (version 2.0, IDBS).
Filter-binding IC 50 protocol
The RFARKGSLRQKNV peptide was the phosphate acceptor for hPKA filter-binding assays. The kinase reactions for the filterbinding IC 50 determinations consisted of 23 
Screening procedure for the assay technology comparison
Three sets of compounds were used to evaluate and compare PKA assays developed using the ElectroCapture™, filter-binding, and FP technologies. The initial proof of the concept experiment that compared the ElectroCapture™, filter-binding, and FP assays used a small set of purchased known PKA inhibitors. This set included the PKA inhibitors Staurosporin (Sigma), H-7, H-8, H-9, H-89, HA-100, HA-1004, and HA-1077 (Calbiochem). The 2nd experiment that compared the ElectroCapture™, filter-binding, and FP assays used a set of nonfluorescent Lilly library compounds. Finally, the 3rd experiment, which compared only the ElectroCapture™ and filter-binding assay formats, used a set of 56 colored Lilly library compounds. This set of compounds had been identified as fluorescent and was known to interfere in the FP assay format (data not shown); these compounds were chosen to determine if they would interfere in the ElectroCapture™ assay as well.
Data analysis
To achieve an adequate signal and still remain under initial velocity reaction conditions, the ElectroCapture™ assay kinase reactions were conducted at 4.5*K M ATP and 0.5*K M for peptide substrate. To properly compare the results obtained in the ElectroCapture™ assay to those obtained in the filter-binding and FP assays, it was necessary to convert the IC 50 data to K i app data using the Cheng-Prusoff equation for competitive inhibitors, K i app = IC 50 /(1 + ([S]/K M )), where [S] is 45 µM or 10 µM ATP for the ElectroCapture™ or FP and filter-binding assays, respectively, and K M for ATP for hPKAα is 10 µM. 12 Using this equation, the calculated K i app = IC 50 /2 for FP and filter-binding assays, and the calculated K i app = IC 50 /5.5 for the ElectroCapture™ assay. The K i app data were then converted to pK i app (-Log 10 K i app ), which was then analyzed in JMP (SAS Institute) using the Y × X regression platform with 95% density ellipse fits.
RESULTS AND DISCUSSION
Kinetic parameters
The K M app values were determined for hPKA using the ElectroCapture™ and FP methods described above (see ElectroCapture™ fit results in Fig. 3 Table 1 ). The K M app value for ATP using ElectroCapture™ was determined to be 14.6 ± 4.2 µM, which is consistent with the 12.0 ± 2.5 µM obtained using FP and the values of 8 to 21 µM reported in the literature. The K M app value for kemptide was determined to be 14.5 ± 1.5 µM, which is consistent with the values of 5 to 31 µM for mammalian PKA reported in the literature. 10, [13] [14] [15] [16] [17] [18] 
and the summary in
Results for known PKA inhibitors
The IC 50 and pK i app values obtained in the ElectroCapture™, filter-binding, and FP assay formats for the known PKA inhibitor set are summarized in Table 2 . The pK i app values obtained by the ElectroCapture™ assay were comparable, within 3-fold of those obtained in the filter-binding and FP formats, and showed a significant correlation (r = 0.99) in the JMP Y × X regression platform plots in Figure 4 . These results confirm that at least for the pur- chased nonselective PKA inhibitors, the ElectroCapture™, FP, and filter-binding assays provide equivalent K i app data.
Results for nonfluorescent library inhibitor set
To be able to accurately compare the results obtained from ElectroCapture™, FP, and filter-binding assays, it was imperative that fluorescent compounds be identified (i.e., as they could appear as false positives and dramatically affect the IC 50 19 ). Fluorescent compounds can be identified using the postquench assay parallel and perpendicular fluorescence data (the raw data used to calculate mP) to calculate the fluorescence intensity value I for each well using the formula I = I p + 2I s .
In this formula, I p is the intensity of the fluorescent emission in the plane parallel to the excitation polarizer, and I s is the intensity of the fluorescent emission in the perpendicular plane. 20 Because the fluorescence measured in the control wells is due only to the fluorescein-labeled tracer, whereas the fluorescence measured in the compound wells represents the sum of the fluorescence from the fluoroscein-labeled tracer and the fluorescence arising from the compounds, compound wells with I values higher than control wells can be flagged during data analysis. 21 Using this assessment, compounds with I values of ≥115% are flagged as fluorescent (a more stringent value than the 120% threshold suggested by Sportsman et al. 20 ), the IC 50 data are rejected, and the compound is retested in the filter-binding assay format. Using this method of fluorescence testing, none of the compounds in this set were rejected due to fluorescence interference. The IC 50 data for this set of compounds were converted to pIC 50 (-Log 10 IC 50 ) and analyzed in the JMP Y × X regression platform (Fig. 5.) Because the assays were run at 2 different concentrations of adenosine triphosphate, the IC 50 data were converted to K i app data using the Cheng-Prusoff equation for competitive inhibitors (K i app = IC 50 /(1 + ([S]/KM)). 12 Using this equation, the calculated K i app = IC 50 /2 for fluorescence polarization (FP) and filter-binding assays and the calculated K i app = IC 50 / 5.5 for the ElectroCapture™ assay. The K i app values that were obtained are comparable between the 3 assay formats.
Electrophoretic Fluorescent Protein Kinase A Assay
Fluorescent compound set
As previously described, the IC 50 was converted to pIC 50 (-Log 10 IC 50 ), and then the pIC 50 data were used in the JMP Y × Y regression platform. These data are summarized in Figure 6 . As previously observed with the nonfluorescent compound set, a good correlation (r = 0.96) was achieved when pK i app values for ElectroCapture™ were compared with those generated in the filter-binding assay. Although a limited data set, this suggests that the ElectroCapture™ assay is highly resistant to interference by fluorescent compounds.
CONCLUSION
The PKA ElectroCapture™ assay described here is a sensitive, robust, nonradioactive microplate-based fluorescent electrophoretic assay. The PKA ElectroCapture™ assay developed uses a lissamine-rhodamine-labeled kemptide peptide substrate, 384well ElectroCapture™ plates, and the ElectroCapture™ HTS Workstation to screen ATP-competitive inhibitors of PKA. In this comparison, the PKA ElectroCapture™ assay was successfully used to experimentally determine enzyme kinetics as well as IC 50 (K i app ) values of commercially available PKA inhibitor com- Of the 71 compounds tested, 16 were excluded from the statistical analysis. Six compounds were excluded because they were inactive in all formats (IC 50 > 20 µM), and 10 were excluded because they were only minimally active, producing extrapolated dose-response curve fits that failed to meet internal assay acceptance criteria (top and bottom curve fits must be within ±10% of 100% and 0%). The correlation analysis demonstrates that good correlation of pK i app results between the 3 assay formats were obtained (r = 0.98, 0.98, and 0.99 respectively).
pounds, in addition to both colored and noncolored library compound inhibitors. The assay is reproducible ( Fig. 7) and robust, providing a good signal window and acceptable Z factor (Table  3) . 22, 23 The data are comparable to those provided by historic FP and filter-binding assay formats, as confirmed by the significant correlation (r = 0.99) of pK i app values between the ElectroCapture™ and the FP and filter-binding assay formats. Our data also indicate that the ElectroCapture™ assay is not susceptible to fluorescence interference as is the FP assay, demonstrated by the lack of fluorescent compound interference observed with a fluorescent compound set. This resistance to fluorescent compound interference is likely due to the physical separation of the compound and the lissamine-rhodamine phosphopeptide that takes place during the electrophoretic capture step. We speculate that only fluorescent compounds possessing a net negative charge at pH 8.0 could potentially co-migrate with the lissamine-rhodamine phosphopeptide and thus interfere in the ElectroCapture™ assay. To date, no interference from fluorescent compounds (including those that were negatively charged) has been observed with ElectroCapture™ (present data and Aventis). 24 However, if encountered, these compounds would appear as false positives in the assay, and their true IC 50 would need to be confirmed in a secondary filter-binding assay. The ElectroCapture™ separation step takes less than 15 min; there is a single wash step (which can be omitted in many cases, signal/noise permitting), and the plate can be read immediately on any capable 384-well fluorescence reader with a read time of less than 5 min for 384 data points. In addition, the ElectroCapture™ assay can accommodate a wide range of ATP and peptide substrate concentrations and does not have a postkinase reaction development step (e.g., for the Z′-LYTE™ PKA assay, this required a 1-h postkinase reaction development step). 25 Finally, because the ElectroCapture™ assay uses a standard footprint 384-well plate, the ElectroCapture™ plate can be used in most HTS liquid-handling and robotic systems. (Although our intention for the beta test was to validate the ElectroCapture™ assay format for low-to-medium throughput lead optimization, a newer production model of the ElectroCapture™ has been developed that can be interfaced with a robotic arm. The utility of the ElectroCapture™ technology has been demonstrated for HTS at both Nanogen and Aventis. 26, 27 ) In conclusion, we find that the ElectroCapture™ method represents a viable alternative to filter binding and FP. However, with such a wide variety of other nonradioactive, antibody-free kinase assays available (e.g., IMAP Of the 43 compounds tested, 18 were excluded from the statistical analysis. Twelve compounds were excluded because they were inactive in all formats (IC 50 > 20 µM), and 6 were excluded because they were only minimally active, producing extrapolated dose-response curve fits that failed to meet internal assay acceptance criteria (top and bottom curve fits must be within ±10% of 100% and 0%). The correlation analysis demonstrates that good correlation of pK i app results using the ElectroCapture™ assay were obtained as compared with the filter-binding (FB) assay format. The table shows the average signal to background (S/B), signal window, and Z factor that were achieved in the assays during the evaluation. Signal window is defined as the overall window between the average maximum, and average minimum signals are defined in standard deviation units. 
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